Next-Generation Breast Cancer Diagnostic and Screening Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), others), by Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others), by Cancer Sub-Type (Luminal A, Luminal B, Triple Ne
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationNext-Generation Breast Cancer Diagnostic and Screening Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented by Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), others), by Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others), by Cancer Sub-Type (Luminal A, Luminal B, Triple Ne
| Forecast Period | 2024-2028 |
| Market Size (2022) | 2.90 billion |
| CAGR (2023-2028) | 10.51% |
| Fastest Growing Segment | Next Generation Sequencing |
| Largest Market | North America |
Market Overview
Global Next-Generation Breast Cancer Diagnostic and Screening Market has valued at USD 2.90 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 10.30% through 2028.
Ongoing technological advancements in breast imaging, genetic testing, and molecular diagnostics have improved the accuracy and early detection of breast cancer, driving demand for these technologies.
Key Market Drivers
Advancements in Technology
Digital mammography has largely replaced traditional film mammography. It offers improved image quality, easier storage and retrieval of images, and the ability to enhance and manipulate images for better visualization of breast tissue. 3D Mammography (Tomosynthesis) also known as breast tomosynthesis, this technology captures multiple X-ray images of the breast from different angles and creates a 3D image. It reduces false positives and improves the detection of breast cancer, particularly in women with dense breast tissue. Breast Magnetic Resonance Imaging (MRI) uses powerful magnets and radio waves to create detailed images of breast tissue. It is especially useful for assessing the extent of disease and detecting tumors in women at high risk. Advanced ultrasound technology, including elastography and contrast-enhanced ultrasound, provides additional information about breast lesions and can help distinguish between benign and malignant tumors. Genetic testing for breast cancer risk has advanced significantly. Next-generation sequencing allows for the analysis of multiple genes simultaneously, providing a comprehensive assessment of genetic mutations associated with breast cancer.
Liquid biopsy techniques involve analyzing biomarkers, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and microRNAs, in a blood sample. These tests can provide real-time information about cancer status and treatment response. AI algorithms are being developed to analyze mammograms and other medical images for signs of breast cancer. AI can improve accuracy and efficiency in breast cancer diagnosis, reducing false positives and false negatives. Technologies like gene expression profiling and proteomics are used to characterize breast cancer at the molecular level. This information helps determine the best treatment options and predict patient outcomes. The integration of telemedicine and remote monitoring solutions allows for breast cancer screening and follow-up care without the need for in-person visits, enhancing access to diagnostic services. Digital pathology enables pathologists to view and analyze tissue samples remotely, improving efficiency and enabling collaboration among experts for more accurate diagnosis. Advanced computational models and algorithms have been developed to assess an individual's breast cancer risk based on a combination of factors, including genetics, family history, and lifestyle. Emerging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are being explored for their potential in breast cancer diagnosis and staging. Immunohistochemistry (IHC) techniques have been refined to provide more accurate characterization of breast cancer subtypes and biomarkers, guiding treatment decisions. This factor will help in the development of
Expanding Applications of Genomic Sequencing
Genomic sequencing, the process of determining the complete DNA sequence of an organism's genome, has expanded its applications across various fields of science and medicine. One of the most notable areas of expansion is in healthcare and genetics.
Genomic sequencing is applied in agriculture to improve crop breeding, increase crop yield, and develop disease-resistant plant varieties. It also helps trace the origin of foodborne outbreaks and ensure food safety. Environmental DNA (eDNA) sequencing is used to study biodiversity and ecosystems. It helps identify species in environmental samples, monitor invasive species, and assess the impact of environmental changes. Genomic sequencing is used in forensic science for human identification, paternity testing, and solving criminal cases. It provides a powerful tool for identifying suspects and victims based on DNA evidence. Genomic sequencing allows scientists to study the evolutionary history and relationships between species. Comparative genomics helps uncover genetic adaptations and the genetic basis of evolutionary traits. With the expansion of genomic data, bioinformatics tools and data analysis techniques are essential for managing, analyzing, and interpreting large-scale genomic datasets. This field continues to evolve alongside genomic sequencing technologies. Genomic sequencing is increasingly used for health and wellness purposes, such as identifying genetic predispositions to certain conditions, optimizing nutrition and fitness plans, and providing insights into ancestry and genealogy. This factor will pace up the demand of Global Next-Generation Breast Cancer Diagnostic and Screening Market.
Rising Awareness and Early Detection Campaigns
Awareness campaigns provide essential information about breast cancer risk factors, signs, symptoms, and the benefits of early detection. This education empowers individuals to make informed decisions about their health and screening options. Awareness initiatives often promote adherence to recommended breast cancer screening guidelines, which may include mammography, genetic testing, clinical breast exams, and self-breast exams. Encouraging adherence to these guidelines drives demand for screening services. Breast cancer awareness campaigns help reduce the stigma associated with cancer and dispel fears related to screening procedures. When individuals are more informed and less fearful, they are more likely to undergo recommended screenings. Early detection of breast cancer is associated with better treatment outcomes and improved survival rates. Awareness campaigns emphasize the importance of detecting cancer at an early, more treatable stage, motivating individuals to seek screening services. Many awareness campaigns target specific populations, including women of certain age groups, ethnic backgrounds, or those with known risk factors. Targeted outreach efforts increase awareness and screening rates within these populations.
Awareness campaigns often include information about where and how to access breast cancer screening services. This information makes it easier for individuals to schedule screenings and seek care. Awareness campaigns often advocate for funding and support for breast cancer research. This research leads to advancements in screening technologies and diagnostic methods, increasing the availability of next-generation tools. These campaigns emphasize the importance of individual agency in healthcare decisions. Empowered patients are more likely to engage in preventive healthcare measures like screening. Many breast cancer awareness campaigns involve local communities, healthcare providers, and advocacy organizations. These collaborations foster a sense of community support and encourage individuals to prioritize their health. Sharing the stories of breast cancer survivors who benefited from early detection and treatment can inspire others to prioritize screening and early intervention. Awareness campaigns have a global impact by raising awareness about breast cancer in regions with limited access to healthcare. These campaigns contribute to international efforts to combat breast cancer. Awareness campaigns can influence healthcare policies and regulations, advocating for improved access to screening services, insurance coverage, and research funding. This factor will accelerate the demand of
Key Market Challenges
Ethical and Legal Issues
As next-generation diagnostic and screening methods generate large volumes of sensitive patient data, ensuring privacy and data security becomes paramount. Ethical concerns arise regarding the storage, sharing, and protection of patient genetic and medical information. Patients must provide informed consent before undergoing genetic testing or other screening procedures. Ensuring that patients fully understand the implications of the tests, including potential psychological and medical consequences, is an ethical imperative. Concerns about genetic discrimination in employment, insurance, and other areas may deter individuals from undergoing genetic testing. Legal protections against such discrimination are essential to address these concerns. Ethical and legal questions arise about who owns the genetic and medical data generated through screening. This includes issues related to data access, sharing, and commercialization. Next-generation screening technologies must adhere to regulatory standards to ensure safety, accuracy, and efficacy. Navigating the complex regulatory landscape can be a challenge for companies and healthcare providers. Ethical issues related to healthcare equity and access arise when next-generation screening technologies are not equally found at to all populations. Disparities in access can lead to unequal health outcomes.
Cost and Accessibility
Many next-generation breast cancer screening and diagnostic methods, such as genetic testing, molecular profiling, and advanced imaging techniques, can be expensive. The cost of equipment, laboratory testing, and data analysis can be a barrier to access for both patients and healthcare providers. Socioeconomic disparities can affect access to advanced breast cancer screening. Low-income individuals and underserved populations may face difficulties in accessing these services due to financial constraints and limited healthcare resources. The availability and extent of insurance coverage for next-generation breast cancer screening and diagnostics vary by region and healthcare system. Lack of adequate insurance coverage can limit access for many patients, making these services financially out of reach. Access to advanced diagnostic centers, specialized expertise, and next-generation technologies may be limited in rural or remote areas. Geographic barriers can hinder individuals from undergoing timely screenings and diagnostics. In some regions, a lack of healthcare infrastructure and resources can limit access to advanced screening and diagnostic services. This includes the availability of trained healthcare professionals and specialized facilities. The high cost of next-generation technologies can be particularly challenging for healthcare systems in developing countries, where resources are limited. This can result in disparities in breast cancer detection and care on a global scale.
Key Market Trends
Integration of Multi-Omics Data
Multi-omics approaches enable healthcare providers to obtain a detailed profile of breast cancer at the molecular level. This includes information on genetic mutations, gene expression patterns, protein activity, metabolite levels, and epigenetic modifications. Integration of multi-omics data allows for precise molecular subtyping of breast cancer, which helps tailor treatment strategies based on the unique characteristics of each patient's tumor. This approach enhances the effectiveness of targeted therapies and minimizes unnecessary treatments. Multi-omics data analysis can identify biomarkers associated with early-stage breast cancer and risk prediction. This aids in early detection and risk assessment, enabling healthcare providers to intervene at an earlier, more treatable stage. Multi-omics analysis identifies specific molecular targets within breast cancer cells that can be exploited for treatment. This leads to the development of targeted therapies and more effective treatment options. Multi-omics data can be used to monitor a patient's response to treatment over time. Changes in gene expression, protein activity, or metabolite levels can indicate treatment efficacy or the need for therapeutic adjustments.
Segmental Insights
Technology Insights
In 2022, the Global Next-Generation Breast Cancer Diagnostic and Screening Market dominated by immunohistochemistry (IHC) segment and is predicted to continue expanding over the coming years.
Biomarker Insights
In 2022, the Global Next-Generation Breast Cancer Diagnostic and Screening Market dominated by BRCA1/2 segment and is predicted to continue expanding over the coming years.
Cancer Sub-Type Insights
In 2022, the Global Next-Generation Breast Cancer Diagnostic and Screening Market dominated by luminal A segment and is predicted to continue expanding over the coming years.
Offering Insights
In 2022, the Global Next-Generation Breast Cancer Diagnostic and Screening Market dominated by services segment and is predicted to continue expanding over the coming years.
End User Insights
In 2022, the Global Next-Generation Breast Cancer Diagnostic and Screening Market was dominated by hospitals and clinics segment in the forecast period and is predicted to continue expanding over the coming years.
Regional Insights
The North America region dominates the Global Next-Generation Breast Cancer Diagnostic and Screening Market in 2022. North America, particularly the United States and Canada, boasts a well-developed healthcare infrastructure with a high level of investment in medical technology and research. This infrastructure supports the adoption of advanced diagnostic and screening technologies.
Recent Developments
- In March 2023, TheRaDaR assay, a liquid biopsy test for molecular/minimal residual disease (MRD),has been made commercially available, according to NeoGenomics, Inc., a topprovider of oncology testing and international contract research services. Thecirculating tumour DNA (ctDNA) that is still present after surgery or othercancer treatments is known as MRD. The CHiRP study, published at ASCO 2022, anddata presentations for the TRACER and cTRAK-TN study cohorts at the most recentSABCS conference are just two recent publications that demonstrate the clinicalutility of the RaDaR test, particularly in the breast cancer space. TheRaDaR assay is a highly sensitive, personalized, tumor-informed technique thatmonitors up to 48 tumor-specific mutations in cell-free DNA (cfDNA) found inthe blood plasma of cancer patients.
- In February 2023, at its HALO BreastCare Centre (HBCC), HALO Precision Diagnostics introduced the HALO Pathway forbreast to save more lives through early detection. To provide moreindividualized care through precision diagnostics all under one roof, ourensemble approach combines modern imaging, population-based analytics, andgenetic testing. In Chico, California, this is the first instance of its kind.With early detection, HALO is changing the healthcare ecosystem. By detectingdisease in stages 1 or 2, when it may be treated with minimally invasivetherapies and survival rates are above 90%, precision medicine is saving morelives. The HALO family now includes a cutting-edge genetic testing facility insouthern California to go along with its existing network of best-in-classbreast screening clinics.
- In January 2023, Avida Biomed, a younglife sciences firm that creates high-performance target enrichment workflowswith distinctive features for clinical researchers using next-generationsequencing (NGS) methods to study cancer, has been acquired by AgilentTechnologies Inc. Agilent's marketleading Sure Select portfolio is enhanced by the acquisition, which alsosupports the company's expansion plans into the dynamic clinical research anddiagnostics industries. Because Agilent's automation platforms, such as Magnisand Bravo, are compatible with Avida BioMed’s chemicals and assays, efficientscaling of research trials and standard sample testing will be made possible.
Key Market Players
- Abbott Laboratories
- Agendia Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Genomics Co., Ltd.
- CENTOGENE N.V
- Danaher Corporation
- Exact Sciences Corporation
- Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Lucence Diagnostics Pte Ltd.
| By Technology | By Biomarker | By Cancer Sub Type | By Offering | By End User | By Region |
| Real-Time PCR Immunohistochemistry (IHC) Next-Generation Sequencing (NGS) Fluorescence In-Situ Hybridization (FISH) Others | BRCA1/2 ER/PR Receptors HER-2 Others | Luminal A Luminal B Triple Negative/Basal Like Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched | Products Services | Hospitals and Clinics Diagnostic Centers, and Reference Labs Academic and Research Institutes | North America Asia-Pacific Europe South America Middle East & Africa |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy